Enigma Biomedical Group and Yale Sign Memorandum of Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology

We today announced execution of a Memorandum of Understanding to license Yale’s Synaptic Density Imaging (SDI) biomarker technology platform. With this license, EBG will be responsible for the global development and commercialization of Yale’s early stage investigational imaging agents using Positron Emission Tomography (PET) to assess neurodegeneration. SDI promises to provide an important new tool in understanding neurodegenerative diseases such as Alzheimer’s and other dementias.